Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.
Profitability
This table compares Anebulo Pharmaceuticals and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anebulo Pharmaceuticals | N/A | -90.11% | -84.53% |
| Orchestra BioMed | -2,367.49% | -289.42% | -110.04% |
Insider and Institutional Ownership
28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 8.1% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anebulo Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
| Orchestra BioMed | 0 | 0 | 4 | 1 | 3.20 |
Anebulo Pharmaceuticals presently has a consensus price target of $5.50, suggesting a potential upside of 125.41%. Orchestra BioMed has a consensus price target of $14.00, suggesting a potential upside of 426.32%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Anebulo Pharmaceuticals.
Risk and Volatility
Anebulo Pharmaceuticals has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Earnings & Valuation
This table compares Anebulo Pharmaceuticals and Orchestra BioMed”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anebulo Pharmaceuticals | N/A | N/A | -$8.20 million | ($0.26) | -9.38 |
| Orchestra BioMed | $2.64 million | 38.93 | -$61.02 million | ($1.83) | -1.45 |
Anebulo Pharmaceuticals has higher earnings, but lower revenue than Orchestra BioMed. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Summary
Orchestra BioMed beats Anebulo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
